Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia. (25th October 2021)

• Record Type: Journal Article
• Authors: Abdel Rahman, Zaid H.; Parrondo, Ricardo D.; Heckman, Michael G.; Wieczorek, Mikolaj; Miller, Kevin C.; Alkhateeb, Hassan; Sproat, Lisa Z.; Murthy, Hemant; Hogan, William J.; Kharfan‐Dabaja, Mohamed A.; Peterson, Jess F.; Baughn, Linda B.; Hoppman, Nicole; Litzow, Mark R.; Ketterling, Rhett P.; Greipp, Patricia T.; Foran, James M.
• Is Part Of: British journal of haematology. Volume 196:Number 4(2022)
• Page Start: 963
• Page End: 968
• Publication Date: 2021-10-25
• Subjects: ALL -- leukemia -- FISH -- therapy‐related; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17906
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: We report a comparative analysis of patients with therapy‐related acute lymphoblastic leukaemia (tr‐ALL) vs de novo ALL. We identified 331 patients with B‐ALL; 69 (21%) were classified as tr‐ALL. The most common prior malignancies were breast (23·2%) and plasma cell disorders (20·3%). Patients with tr‐ALL were older (median 63·2 vs. 46·2 years, P < 0.001), more often female (66·7% vs. 43·5%, P < 0·001), and more likely to have hypodiploid cytogenetics (18·8% vs. 5·0%, P < 0·001). In multivariable analysis, patients with tr‐ALL were less likely to achieve complete remission [odds ratio (OR) = 0·16, P < 0·001] and more likely to be minimal residual disease‐positive (OR = 4·86, P = 0·01) but had similar OS after diagnosis and allo‐haematopoietic cell transplantation.